AutoVPAP Versus VPAP; Assessment of Sleep and Ventilation
Chest Wall Disorder, Neuromuscular Disease
About this trial
This is an interventional treatment trial for Chest Wall Disorder
Eligibility Criteria
Inclusion Criteria: Patients aged 18-80 years Nocturnal hypoventilation (nocturnal peak transcutaneous PCO2 > 6.5 kPa when breathing spontaneously) with Congenital neuromuscular disease (eg. Duchenne muscular dystrophy, congenital muscular dystrophy), acquired neuromuscular disease (eg. old polio, bilateral diaphragm paralysis) or chest wall disease (eg. idiopathic scoliosis, thoracoplasty) Recruited from 1300 patients attending Royal Brompton Hospital Lind ward ventilator clinic. All patients will be familiar with non-invasive ventilation use but currently using a ventilator which is not a VPAP model eg. BiPAP Harmony, Breas PV403. Able to understand treatment and protocol Exclusion Criteria: Unstable respiratory failure (PaO2 < 7.5 kPa, PaCO2 > 8.0 kPa, Uncontrolled heart failure or arrhythmia Moderate or severe bulbar weakness. Unable to understand treatment or protocol
Sites / Locations
- Royal Brompton Hospital